Status:
COMPLETED
Study of a-Interferon With Adriamycin, Bleomycin, Velban, and Dacarbazine (ABVD) With Hodgkin's Disease
Lead Sponsor:
M.D. Anderson Cancer Center
Collaborating Sponsors:
Schering-Plough
Conditions:
Lymphoma
Eligibility:
All Genders
Phase:
PHASE2
Brief Summary
This is a clinical research study of interferon (IFN) plus chemotherapy with the standard combination of Adriamycin, Bleomycin, Velban, and Dacarbazine (ABVD). The treatment will be given to patients ...
Detailed Description
Each treatment cycle will last 2 weeks. On days 1 - 4 of each cycle, patients will be given a shot of IFN under the skin. On day 4, patients will be given ABVD through a vein over one-hour. The plan ...
Eligibility Criteria
Inclusion
- Hodgkin's disease patients who relapse after radiation therapy alone, or in combination with Novantrone, Oncovin, Velban, and Prednisone (NOVP); and previously untreated patients with stage III and IV who are eligible for standard ABVD therapy.
- Must have adequate bone marrow reserve Absolute neutrophil count (ANC) \> 1,000/uL, Platelets \> 100,000
- Left ventricular ejection fraction (LVEF) \>/= 50%, serum creatinine \< 2mg/dl, serum bilirubin \< 2mg/dl
Exclusion
- No prior therapy with Mustargen Oncovin Procarbazine Prednisone (MOPP).
- No severe pulmonary disease including Chronic obstructive pulmonary disease (COPD) and asthma.
Key Trial Info
Start Date :
July 1 1996
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 1 2011
Estimated Enrollment :
35 Patients enrolled
Trial Details
Trial ID
NCT01404936
Start Date
July 1 1996
End Date
December 1 2011
Last Update
February 1 2013
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
UT MD Anderson Cancer Center
Houston, Texas, United States, 77030